Article Details

Roche's Phase 3 Study of Tiragolumab Study Fails to Meet Co-Primary Endpoint - MarketWatch

Retrieved on: 2022-03-30 05:20:22

Tags for this article:

Click the tags to see associated articles and topics

Roche's Phase 3 Study of Tiragolumab Study Fails to Meet Co-Primary Endpoint - MarketWatch. View article details on hiswai:

Excerpt

By Giulia Petroni Roche Holding AG on Wednesday said that a phase 3 study of tiragolumab for the treatment of extensive stage small-cell lung ...

Article found on: www.marketwatch.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up